Incretins are metabolic hormones that are
activated when blood glucose levels decrease in the body.
Incretin-based drugs are used in the treatment of type 2 diabetes. These
drugs are associated with low risk of hypoglycemia and deliver positive
effect on body weight. Oral anti-diabetic drugs often fail to maintain
the desired glucose levels postprandial. This has increased demand for
better and highly efficient therapeutics such as incretin-based drugs.
Incretin-based drugs assist in increasing
the secretion of insulin in the body by acting on pancreatic beta
cells. These also help in inhibiting the discharge of glucagon by acting
on pancreatic alpha cells. Two types of incretin-based drugs are
currently available: DPP-4 inhibitors and incretin mimetics (GLP-1
agonist), which act on the antidiabetic principle of incretin hormone.
Incretins based drug are hormones which
are derived from the gut after the food is ingested. Incretins-based
drugs are categorized into glucagon-like peptide-1 and gastric
inhibitory peptide. These molecules get inactivated by the use of enzyme
Dipeptidyl Peptidase-4 (DPP-4). Increasing demand for highly efficient
therapeutics has resulted in incertin based drug market during the
forecast period. Incertin-based drugs are prescribed when traditional
oral anti-diabetic drugs fail to maintain the desired levels of glucose
postprandial. Incertin-based drugs assist in increased insulin secretion
and also helps in inhibiting the release of glucagon by acting on the
pancreatic cells. According to reports, the U.S. has nearly 26 million
diabetic patients and the European Union has 35 million.
The global incretin-based drugs market
can be segmented based on drug type, route of administration,
distribution channel, and region. In terms of drug type, the market can
be categorized into dipeptidyl peptidase-4 inhibitors, and glucagon-like
peptide-1 receptor agonists. Based on route of administration, the
global incertin-based drugs market can be divided into oral and
intravenous. In terms of distribution channel, the global incertin-based
drugs market can be divided into hospital pharmacies, retail
pharmacies, and e-pharmacies.
Major drivers of the global
incertin-based drug market are increase in research activity, government
initiatives in promoting disease awareness & research grants, rise
in product development, growing population, increase in per capita
income in emerging countries, and surging health care expenditure are
factors expected to fuel the growth of the global incertin-based drugs
market during the forecast period. However, lack of favorable
reimbursement policies in emerging economies, poor access to drugs,
safety & efficacy concerns associated with incertin-based drugs, and
high treatment cost are likely to restrain the global incertin-based
drug market during the forecast period.
Geographically, the global incertin-based
drugs market can be segmented into North America, Europe, Asia Pacific,
Latin America, and Middle East & Africa. North America leads the
market largely due of surging patient pool, rising presence of leading
manufacturers, increasing research, and increasing product launches
through advance drug development. North America was followed by Europe
and Asia Pacific. Stringent drug regulation to ensure safety and
effectiveness of drugs by the USFDA and EMA for treating diabetes and
other chronic diseases are expected to drive the global incertin-based
drug market during the forecast period. The market in Latin America and
Middle East & Africa is expected to be driven by changing
demographics, expanding health care infrastructure, and increased
participation of global pharmaceutical manufacturers in the regions
through public private partnership to increase research and production
activities.
Major players operating in the global
incretin-based drugs market are Sanofi, Novartis AG, Johnson &
Johnson, Eli Lilly and Company, AstraZeneca plc, Merck & Co., Inc.,
Takeda Pharmaceutical Company Ltd, and GlaxoSmithKline plc, among
others.
No comments:
Post a Comment